Recent News

• 04.02.2026 - Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026
• 04.01.2026 - Calidi Biotherapeutics to Present New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026
• 03.12.2026 - Calidi Biotherapeutics Presents its Innovative and Scalable Manufacturing Process for CLD-401 at the 9th Annual Bioprocessing Summit; FDA Feedback Support Company’s Approach to Manufacturing
• 02.20.2026 - Calidi Biotherapeutics Presents Data on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform at the 2026 AACR-IO Conference
• 02.12.2026 - Calidi Biotherapeutics To Present on its New Approach to Bispecific T-Cell Engagers (BiTEs) Using its RedTail Platform in a Late-Breaking Abstract at the 2026 AACR-IO Conference

Recent Filings

• 04.02.2026 - 8-K Current report
• 03.31.2026 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 03.27.2026 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.27.2026 - 8-K Current report
• 03.27.2026 - EX-99.1 EX-99.1
• 03.11.2026 - EX-99.1 EX-99.1
• 03.11.2026 - 8-K Current report
• 03.09.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 03.09.2026 - SCHEDULE 13D General Statement of Acquisition of Beneficial Ownership
• 03.06.2026 - 424B5 Prospectus [Rule 424(b)(5)]